Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vericiguat - Bayer HealthCare Pharmaceuticals/Merck & Co

Next Previous
Drug Profile

Vericiguat - Bayer HealthCare Pharmaceuticals/Merck & Co

Alternative Names: BAY 102; BAY-1021189; MK-1242; VERQUVO

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Merck & Co
  • Class Amines; Carbamates; Fluorobenzenes; Heart failure therapies; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic heart failure
  • Phase II Metabolic syndrome
  • No development reported Coronary artery disease

Most Recent Events

  • 05 Feb 2025 Merck Sharp & Dohme completes the Phase-III VICTOR trial in Chronic heart failure in Italy, Poland, Sweden, Sweden, Brazil, Argentina, Canada, Chile, China, Colombia, Czech Republic, Denmark, France, Greece, Guatemala, Hong Kong, Ireland, South Africa, South Korea, Israel, Germany, Malaysia, Mexico, New Zealand, Peru, Singapore, Taiwan, Turkey, Ukraine, United Kingdom, Russia (PO) (NCT05093933)
  • 01 Oct 2024 Phase-II/III clinical trials in Chronic heart failure (In adolescents, In children, In infants, In neonates) in Mexico (PO) (NCT05714085)
  • 29 Jul 2024 Bayer completes a phase IIb trial for Chronic heart failure in USA, Argentina, Hungary, Italy, Poland, Spain, Sweden (PO, Tablet) (NCT06195930)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top